Raze debuts with $24M series A

Raze Therapeutics Inc. (Cambridge, Mass.) raised $24 million in a series A round with Atlas Venture; MPM Capital; MS Ventures; Partners Innovation Fund; Astellas Venture Management; and Novartis AG (NYSE:NVS; SIX:NOVN). Atlas' Peter Barrett is chairman of the cancer company and the firm's Jason Rhodes is a director and acting CEO. Other directors include Ansbert Gadicke of MPM, Nilesh Kumar of MS Ventures and Reza Halse of Partners Innovation Fund. ...